2. Search Result
Search Result
Results for "

metastatic melanoma

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

1

Fluorescent Dyes

2

Biochemical Assay Reagents

3

Peptides

8

Inhibitory Antibodies

2

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9901
    Ipilimumab
    4 Publications Verification

    MDX-010; BMS-734016

    		 CTLA-4 Cancer
    Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .
    Ipilimumab
  • HY-B0078
    Dacarbazine
    10+ Cited Publications

    Imidazole Carboxamide

    		 Nucleoside Antimetabolite/Analog Apoptosis Cancer
    Dacarbazine is a nonspecific antineoplastic (antineoplastic) alkylating agent. Dacarbazine inhibits T and B lymphocyte responses with IC50 of 50 and 10 μg/mL, respectively. Dacarbazine can be used in the study of metastatic malignant melanoma .
    Dacarbazine
  • HY-W1126504
    ETN029

    MC339

    		 Notch Cancer
    ETN029 (MC339) is a selective DLL3 ligand. ETN029 labeled with 225Ac has dose-dependent cytotoxicity in SCLC, NEPC and metastatic melanoma cells and increases the phosphorylation of H2AX expression. ETN029 labeled with 177Lu shows rapid uptake persistent tumor retention and favorable tumor-to-kidney ratio. ETN029 can be used for cancers like SCLC and NEPC imaging and research .
    ETN029
  • HY-16661
    Skp2 Inhibitor C1
    5+ Cited Publications

    SKPin C1

    		 E1/E2/E3 Enzyme Cancer
    Skp2 Inhibitor C1 (SKPin C1) is an S-phase kinase-related protein 2 (Skp2) inhibitor with an inhibitory effect on metastatic melanoma cells. Skp2 Inhibitor C1 slows the cell cycle, inhibits cell proliferation, and triggers apoptosis .
    Skp2 Inhibitor C1
  • HY-120599
    Sabizabulin
    4 Publications Verification

    VERU-111; ABI-231

    		 Microtubule/Tubulin Apoptosis HPV Cancer
    VERU-111 (ABI-231) is a potent and orally active α and β tubulin inhibitor, which displays strong antiproliferative activity, with an average IC50 of 5.2 nM against panels of melanoma and prostate cancer cell lines. VERU-111 (ABI-231) suppresses tumor growth and metastatic phenotypes of cervical cancer cells via targeting HPV E6 and E7, and has potential for the treatment of prostate cancer .
    Sabizabulin
  • HY-P99049
    Sotigalimab

    APX005M; APX005M; EPI-0050

    		 TNF Receptor Inflammation/Immunology
    Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma .
    Sotigalimab
  • HY-P9918
    Tremelimumab

    Ticilimumab; CP-675206

    		 CTLA-4 Inflammation/Immunology Cancer
    Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .
    Tremelimumab
  • HY-P99291
    Etaracizumab

    LM609; MEDI-522

    		 Integrin Apoptosis Akt Cancer
    Etaracizumab (LM 609) is an αvβ3 integrin IgG mAb. Etaracizumab is developed to target αvβ3+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofαvβ3-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Etaracizumab
  • HY-118487
    OB-24
    2 Publications Verification

    		 Heme Oxygenase (HO) Reactive Oxygen Species (ROS) Cancer
    OB-24 is a selective small-molecule HO-1 inhibitor (IC50 = 1.9 μM for HO-1 and IC50 for HO-2 >100 μM). OB-24 possesses anti-tumor and anti-metastatic properties. OB-24 can be studies in research such as prostate cancer, melanoma, ovarian carcinoma and lung metastasis .
    OB-24
  • HY-N6893
    Ergolide
    3 Publications Verification

    		 NF-κB NOD-like Receptor (NLR) Apoptosis Autophagy Neurological Disease Cancer
    Ergolide is an orally active dual inhibitor targeting NF-κB/p65 and NLRP3. Ergolide blocks the NF-κB signaling pathway and the nuclear translocation of p65, and irreversibly binds to the NACHT domain of NLRP3 to inhibit inflammasome assembly. Ergolide significantly reduces the production of inflammatory mediators (e.g., NO, PGE2) and cytokines, induces cancer cell apoptosis, autophagy and ROS generation. Ergolide also enhances the anti-tumor effect of vincristine. Ergolide alleviates acute lung injury via an NLRP3-dependent mechanism, and effectively improves the survival rate and behavioral function of septic mice and inflammatory zebrafish models. Ergolide is used in the research of metastatic uveal melanoma, neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease), sepsis and acute lymphoblastic leukemia .
    Ergolide
  • HY-177120
    DMBP

    		Autophagy Cancer
    DMBP is a VPS41 inhibitor. DMBP induces methuosis and inhibits autophagy in cancer cells. DMBP inhibits the fusion of late endosomes and autophagosomes with lysosomes. DMBP effectively inhibits metastasis in a mouse metastatic melanoma model. DMBP can be used for the study of melanoma .
    DMBP
  • HY-W001939
    4-Acetylbenzoic acid

    		Biochemical Assay Reagents Cancer
    4-Acetylbenzoic acid is a Zn(II) complex. 4-Acetylbenzoic acid is a derivative of benzoic acid that is commonly used in chemical synthesis. 4-Acetylbenzoic acid has an IC50 of 331.3 μM in murine L929 fibroblasts and an IC50 of 176 μM in metastatic melanoma B16 F10 cell lines .
    4-Acetylbenzoic acid
  • HY-123009
    KCN1

    		HIF/HIF Prolyl-Hydroxylase Histone Acetyltransferase Cancer
    KCN1 is a p300/HIF-1α interaction inhibitor. KCN1 inhibits HIF transcriptional activity by binding to the CH1 domain of p300 and preventing the p300/HIF-1α assembly. KCN1 exerts antitumor activities through cell cycle arrest .
    KCN1
  • HY-124939
    ND-322 hydrochloride

    		MMP Cancer
    ND-322 hydrochloride is a potent and selective water-soluble gelatinase inhibitor. ND-322 hydrochloride reduces melanoma tumor growth and delays metastatic dissemination .
    ND-322 hydrochloride
  • HY-113612
    Cytostatin

    		Phosphatase Apoptosis Cancer
    Cytostatin is an effective and selective protein phosphatase 2A (PP2A) inhibitor with an IC50 value of 210 nM. Cytostatin exhibits anti-metastatic properties, good antitumor activity, and can induce apoptosis. Cytostatin can also prevent the adhesion of B16 melanoma cells to components of the extracellular matrix (laminin and collagen). Cytostatin belongs to the family of natural product fosriecin .
    Cytostatin
  • HY-B0078B
    Dacarbazine hydrochloride

    Imidazole Carboxamide hydrochloride

    		 Antibiotic Cancer
    Dacarbazine hydrochloride is a cell cycle nonspecific antineoplastic alkylating agent. Dacarbazine hydrochloride inhibits T and B lymphoblastic response, with IC50 values of 50 and 10 μg/mL, respectively. Dacarbazine hydrochloride can be used for the research of metastatic malignant melanoma .
    Dacarbazine hydrochloride
  • HY-150639
    Everafenib

    		Raf Cancer
    Everafenib is a potent and blood-brain barrier (BBB) penetrant BRAF inhibitor, also inhibits MAPK signaling. Everafenib has inhibitory activity against a panel of V600EBRAF melanoma cell lines with IC50 values of 2-10 nM, which is better than Dabrafenib (HY-14660) and Vemurafenib (HY-12057). Everafenib has efficacy in an intracranial mouse model of metastatic melanoma .
    Everafenib
  • HY-B0078A
    Dacarbazine citrate

    Imidazole Carboxamide citrate

    		 Apoptosis Antibiotic Cancer
    Dacarbazine citrate is a cell cycle nonspecific antineoplastic alkylating agent. Dacarbazine citrate inhibits T and B lymphoblastic response, with IC50 values of 50 and 10 μg/mL, respectively. Dacarbazine Citrate can be used for the research of apoptosis and various cancers such as metastatic malignant melanoma .
    Dacarbazine citrate
  • HY-B0078R
    Dacarbazine (Standard)

    Imidazole Carboxamide (Standard)

    		 Apoptosis Nucleoside Antimetabolite/Analog Reference Standards Cancer
    Dacarbazine (Standard) is the analytical standard of Dacarbazine. This product is intended for research and analytical applications. Dacarbazine is a nonspecific antineoplastic (antineoplastic) alkylating agent. Dacarbazine inhibits T and B lymphocyte responses with IC50 of 50 and 10 μg/mL, respectively. Dacarbazine can be used in the study of metastatic malignant melanoma .
    Dacarbazine (Standard)
  • HY-149950
    Anticancer agent 106

    		Apoptosis Cancer
    Anticancer agent 106 (compound 10ic) is an anticancer agent that induces apoptosis in B16-F10 melanoma cells. Anticancer agent 106 also potently inhibits metastatic nodules in a mouse model of lung metastatic melanoma. Anticancer agent 106 can be used in the study of cancer, especially lung metastatic melanoma .
    Anticancer agent 106
  • HY-149949
    Anticancer agent 105

    		Apoptosis Cancer
    Anticancer agent 105 is a compound based on thienopyrimidine scaffold, with with good safety and anticancer properties. Anticancer agent 105 shows selective toxicity towards melanoma cancer, and induces apoptosis. And Anticancer agent 105 significantly inhibits the metastatic nodules, even in pulmonary metastatic melanoma mouse model .
    Anticancer agent 105
  • HY-149951
    Anticancer agent 107

    		Others Cancer
    Anticancer agent 107(Compd 11jc) has significant antitumor activity and can be used as an anticancer agent in the study of pulmonary metastatic melanoma .
    Anticancer agent 107
  • HY-126160
    CB10-277

    		Nucleoside Antimetabolite/Analog DNA Alkylator/Crosslinker Cancer
    CB10-277 is a Dacarbazine (HY-B0078) analog that mediates alkylation of guanine residues at the O 6 position in DNA and subsequently reduces ATase levels in lymphocytes and tumors. CB10-277 is useful in the study of metastatic malignant melanoma .
    CB10-277
  • HY-113612A
    Cytostatin sodium

    		Apoptosis Phosphatase Cancer
    Cytostatin sodium is an effective and selective protein phosphatase 2A (PP2A) inhibitor with an IC50 value of 210 nM. Cytostatin sodium exhibits anti-metastatic properties, good antitumor activity, and can induce apoptosis. Cytostatin sodium can also prevent the adhesion of B16 melanoma cells to components of the extracellular matrix (laminin and collagen). Cytostatin sodium belongs to the family of natural product fosriecin .
    Cytostatin sodium
  • HY-W001939R
    4-Acetylbenzoic acid (Standard)

    		Biochemical Assay Reagents Reference Standards Cancer
    4-Acetylbenzoic acid (Standard) is the analytical standard of 4-Acetylbenzoic acid. This product is intended for research and analytical applications. 4-Acetylbenzoic acid is a Zn(II) complex. 4-Acetylbenzoic acid is a derivative of benzoic acid that is commonly used in chemical synthesis. 4-Acetylbenzoic acid has an IC50 of 331.3 μM in murine L929 fibroblasts and an IC50 of 176 μM in metastatic melanoma B16 F10 cell lines .
    4-Acetylbenzoic acid (Standard)
  • HY-175039
    FAK-IN-28

    		FAK Apoptosis Reactive Oxygen Species (ROS) Caspase Cancer
    FAK-IN-28 is an orally active FAK inhibitor (IC50 = 0.4 nM). FAK-IN-28 exhibits dual antiproliferative and anti-metastatic properties. FAK-IN-28 triggers caspase-3-dependent apoptosis via ROS elevation. FAK-IN-28 inhibits tumor growth without causing weight loss or hepatotoxicity. FAK-IN-28 is useful in the study of FAK-driven malignancies, such as colon cancer, cervical cancer, triple-negative breast cancer, and melanoma .
    FAK-IN-28
  • HY-161778
    ZG-126

    		HDAC VD/VDR Inflammation/Immunology Cancer
    ZG-126 is an agonist for vitamin D receptor (VDR) and an inhibitor for histone deacetylase (HDAC) (IC50=0.63-67.6 μM). ZG-126 exhibits cytotoxicity in cancer cells MDA-MB-231 and 4T1. ZG-126 exhibits antitumor and anti-metastatic efficacy against melanoma and triple-negative breast cancer (TNBC) in mouse models. ZG-126 also exhibits anti-inflammatory activity, through the reduction of macrophage infiltration and immunosuppressive M2-polarization .
    ZG-126
  • HY-P992392
    JM1-24-3

    		Transmembrane Glycoprotein Akt mTOR Cancer
    JM1-24-3 is an anti-MUC18 mouse monoclonal antibody with a Kd value of 1.60e-9 M. JM1-24-3 reduces the phosphorylation levels of p-AKT (Ser473) and p-mTOR (Ser2448) in a time-dependent manner. JM1-24-3 exhibits anticancer activity against melanoma. JM1-24-3 can be used in studies related to metastatic melanoma .
    JM1-24-3
  • HY-182039
    Tubulin polymerization-IN-89

    		Microtubule/Tubulin Caspase Apoptosis Cancer
    Tubulin polymerization-IN-89 is a tubulin polymerization inhibitor. Tubulin polymerization-IN-89 binds to the colchicine-binding site on tubulin heterodimers, disrupting tubulin polymerization and microtubule formation. Tubulin polymerization-IN-89 induces apoptosis in melanoma cells and arrests the cell cycle at the G2/M phase. Tubulin polymerization-IN-89 can be used in studies related to metastatic melanoma .
    Tubulin polymerization-IN-89
  • HY-183629
    ZNF281-IN-1

    		Zinc Finger Protein Apoptosis Cardiovascular Disease Cancer
    ZNF281-IN-1 is a ZNF281 inhibitor. ZNF281-IN-1 disrupts the binding of transcriptionally active DNA-bound ZNF281 to the promoters of target genes including TRIM35 and ZEB1. ZNF281-IN-1 inhibits tumor cell proliferation, stabilizes P53 and upregulates PUMA to induce apoptosis, while triggering cellular senescence. ZNF281-IN-1 completely prevents Doxorubicin (HY-15142A)-induced cardiotoxicity (AIC), and enhances rather than impairs the antitumor efficacy of Doxorubicin. ZNF281-IN-1 completely blocks the distant metastasis of melanoma to the lungs. ZNF281-IN-1 can be used in the research of cardiotoxicity, lung cancer and metastatic melanoma .
    ZNF281-IN-1
  • HY-P992475
    Tecnemab K1

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    Tecnemab K1 is an anti-Melanoma monoclonal antibody. Tecnemab K1 accumulates in metastatic lesions of malignant melanoma and some benign lesions. When radiolabeled, Tecnemab K1 can serve as a radiotracer for malignant melanoma research. The isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977) .
    Tecnemab K1
  • HY-183946
    NVP-TAC544

    		FAK Cancer
    NVP-TAC544 is a focal adhesion kinase (FAK) inhibitor. NVP-TAC544 inhibits angiogenesis. NVP-TAC544 can be used for the research of melanoma (primary or metastatic) .
    NVP-TAC544
  • HY-185050
    Antitumor agent-210

    		IFNAR Cancer
    Antitumor agent-210 (Compound 1778) is an NK cell activator. Antitumor agent-210 has a weak proliferative effect on NK92 cells, promoting the activation and degranulation of NK cells, and significantly enhancing the cytotoxicity of NK92 cells against tumor cells. Antitumor agent-210 promotes the release of cytokine granzyme B, perforin, and IFN-γ. Antitumor agent-210 reduces the number of lung metastatic lesions in mice and can be used for the study of melanoma lung metastasis .
    Antitumor agent-210
  • HY-D3141
    DR probe

    		Cancer
    DR probe is a "dual-key-and-lock" fluorescent probe designed based on the Resorufin (HY-123533) scaffold (Ex/Em = 647 nm/663-738 nm). DR probe can be sequentially activated by hydrogen peroxide to form the intermediate SR, which acts as a tyrosinase substrate to trigger a fluorescence turn-on signal. DR probe can distinguish normal melanocytes from melanoma cells. DR probe supports cell imaging and can be applied to mouse melanoma models to achieve melanoma diagnosis with higher accuracy and lower false-positive rates. DR probe is applicable to relevant research on melanoma .
    DR probe
  • HY-P10370B
    d-(KLAKLAK)2, Proapoptotic Peptide acetate

    		Apoptosis Caspase Cancer
    d-(KLAKLAK)2, Proapoptotic Peptide acetate is a pro-Apoptotic peptide whose core mechanism of action is to disrupt organelle membranes, especially mitochondrial membranes, thereby inducing apoptosis. d-(KLAKLAK)2, Proapoptotic Peptide acetate activates the activity of caspase 3/7 in cancer cells. Although d-(KLAKLAK)2 Proapoptotic Peptide acetate exhibits very low toxicity to eukaryotic cells extracellularly, it cannot effectively penetrate cell membranes to enter the cytoplasm on its own. d-(KLAKLAK)2, Proapoptotic Peptide acetate must be conjugated with a carrier capable of "homing" and "internalization" to exert its anti-cancer effects .
    d-(KLAKLAK)2, Proapoptotic Peptide acetate
  • HY-119601
    GRI918013

    		Phosphodiesterase (PDE) Cancer
    GRI918013 (compound 1) is a selective and competitive autotaxin (ATX/NPP2) inhibitor with anti-invasive and anti-metastatic activity. GRI918013 competitively binds to ATX, blocking lipid substrates such as lysophosphatidylcholine (LPC) from entering the ATX active site, thereby inhibiting ATX-mediated hydrolysis of LPC to lysophosphatidic acid (LPA), and consequently inhibiting ATX-LPA axis-related tumor cell invasion and metastasis. GRI918013 inhibits ATX-mediated hydrolysis of the LPL substrate FS-3 (IC50=31.42 nM, Ki=12.98 nM). GRI918013 can be used in research on cancer invasion and metastasis, such as melanoma, and can also serve as a tool compound for ATX-LPA axis-related diseases such as fibrotic diseases, neuropathic pain, and cholestatic pruritus .
    GRI918013
  • HY-P991964
    Rendomab B4

    Rendomab-B49

    		 Endothelin Receptor Cancer
    Rendomab B4 (Rendomab-B49) is a monoclonal antibody targeting ETB. Rendomab B4 preferentially binds to ETB in the active conformational state and exhibits selectivity for ETB on melanoma cells. Rendomab B4 inhibits the G protein-dependent phospholipase C (PLC) pathway, blocks ET-3-induced Gαi/o-mediated inhibition of adenylate cyclase, and does not affect the activation of the ERK1/2 pathway. Rendomab B4 is applicable to melanoma-related research .
    Rendomab B4
  • HY-181989
    CAIF

    		Glucosylceramide Synthase (GCS) Cancer
    CAIF is an irreversible, selective allosteric covalent inhibitor of ucosyltransferase 8 (FUT8) with an IC50 of 5.7 μM. CAIF inhibits core fucosylation modification in cancer cells, and suppresses the invasion and migration of cancer cells. CAIF is applicable for cancer research .
    CAIF
  • HY-P991896
    AT1412

    AT14-012

    		 Transmembrane Glycoprotein Inflammation/Immunology Cancer
    AT1412 is a CD9-binding antibody. AT1412 binds to the tetraspanin protein CD9 and modulates CD9 function by enhancing T cell adhesion to endothelial cells (HUVECs) and transendothelial migration. AT1412 binds to B-ALL cell lines but not to T-ALL. AT1412 induces antibody-dependent cellular cytotoxicity in B-ALL cell lines. AT1412 binds to melanoma cells, B-ALL, gastric cancer, colorectal cancer, and pancreatic cancer cells [1] .
    AT1412

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: